Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptifibatide in High Risk NSTE-ACS Patients Requiring Urgent CABG
NCT01863134Phase 4Completed
- Sponsor
- Medical University of Silesia
- Start
- Jan 2005
- Primary completion
- Dec 2010
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in Non-ST-elevation acute coronary syndrome (NSTE-ACS) comparing Eptifibatide with Placebo (2 arms). Primary endpoint: Major Adverse Cardiac and Cerebrovascular Events at 12 months. Started Jan 2005; status: completed.
02
Drugs
eptifibatide
03
Conditions
Non-ST-elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT01863134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863134.